(Total Views: 512)
Posted On: 07/22/2020 6:37:42 PM
Post# of 36563
New BARDA award: Pfizer Inc. USA
Product Name: BNT162, a prototype COVID-19 mRNA vaccine
Description:
Pfizer will conduct large-scale manufacturing and fill-finish of 100M doses of its prototype COVID-19 mRNA vaccine, developed in collaboration with BioNTech, for distribution in the US once Emergency Use Authorization or licensure is granted by the FDA.
Unique Impact:
Pfizer’s vaccine candidate is an mRNA vaccine that is delivered in lipid nanoparticles. RNA delivered by these protein-free lipid nanoparticles is believed to eliminate the risk of anti-vector immunity while boosting the level and duration of immune responses. Additionally, the use of mRNA technology potentially allows for rapid manufacturing scale-up that is critical for prevention of COVID-19.
Base Award Amount: 1,950,000,000 (July 20, 2020)
Product Name: BNT162, a prototype COVID-19 mRNA vaccine
Description:
Pfizer will conduct large-scale manufacturing and fill-finish of 100M doses of its prototype COVID-19 mRNA vaccine, developed in collaboration with BioNTech, for distribution in the US once Emergency Use Authorization or licensure is granted by the FDA.
Unique Impact:
Pfizer’s vaccine candidate is an mRNA vaccine that is delivered in lipid nanoparticles. RNA delivered by these protein-free lipid nanoparticles is believed to eliminate the risk of anti-vector immunity while boosting the level and duration of immune responses. Additionally, the use of mRNA technology potentially allows for rapid manufacturing scale-up that is critical for prevention of COVID-19.
Base Award Amount: 1,950,000,000 (July 20, 2020)
(0)
(3)
